Neuroendocrine Tumors (NETs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Neuroendocrine Tumors (NETs) Market Outlook

Thelansis’s “Neuroendocrine Tumors (NETs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuroendocrine Tumors (NETs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Neuroendocrine Tumors (NETs) Overview

Neuroendocrine tumors, arising from neuroendocrine cells, are malignant growths. They are most frequently found in the gastrointestinal tract (48%), lungs (25%), and pancreas (9%). However, they can also develop in other organs like the breast, prostate, thymus, and skin. Neuroendocrine cells can produce hormones, such as serotonin, leading to symptoms like flushing and diarrhea. Additionally, they produce proteins like chromogranin A, which serve as biomarkers for NETs. Neuroendocrine tissues commonly express somatostatin receptors on their cell surfaces. Three clinicopathologic features—grade, differentiation, and stage—determine the biological behavior of NETs. NETs can either be discovered incidentally or suspected due to clinical symptoms. When NETs cause symptoms through hormone secretion, they are termed "functioning," and those that do not produce active hormones are termed "nonfunctioning." Both types present late with nonspecific symptoms, often leading to misdiagnoses. Diagnosing NETs involves pathology testing and integrated hormonal and diagnostic imaging to create a comprehensive diagnostic profile. The standard treatment for NETs involves complete tumor removal, with most localized NETs successfully treated through surgery alone. Several drugs, such as Lutathera (lutetium Lu 177 dotatate), Belzutifan, Streptozotocin, Afinitor (everolimus), Sutent (sunitinib), and Xermelo (telotristat), have received FDA approval for treating NETs.

• The overall incidence of NETs in the USA is 2.89 per 100,000 people annually.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: